JMHC News
Reprocell and JTB Begin Provision of Regenerative Medicine-Grade iPS-Derived Exosomes
Reprocell Inc. and JTB Corporation have commenced the handling of regenerative medicine-grade iPS-derived exosomes (autologous and allogeneic) manufactured by Reprocell. JTB has been appointed as the exclusive distributor and has begun sales to medical institutions and clinics using iPS exosomes through the Japan Health & Research Institute.
https://www.jtbcorp.jp/en/newsroom/2024/07/11_jtb_reprocell_ipsexosome.html
